219 related articles for article (PubMed ID: 38135347)
1. Identification of pan-cancer/testis genes and validation of therapeutic targeting in triple-negative breast cancer: Lin28a-based and Siglece-based vaccination induces antitumor immunity and inhibits metastasis.
Carter JA; Matta B; Battaglia J; Somerville C; Harris BD; LaPan M; Atwal GS; Barnes BJ
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38135347
[TBL] [Abstract][Full Text] [Related]
2. Identification of pan-cancer/testis genes and validation of therapeutic targeting in triple-negative breast cancer: Lin28a- and Siglece-based vaccination induces anti-tumor immunity and inhibits metastasis.
Carter JA; Matta B; Battaglia J; Somerville C; Harris BD; LaPan M; Atwal GS; Barnes BJ
bioRxiv; 2023 May; ():. PubMed ID: 37214884
[TBL] [Abstract][Full Text] [Related]
3. Heterologous prime-boost cellular vaccination induces potent antitumor immunity against triple negative breast cancer.
Niavarani SR; St-Cyr G; Daniel L; Lawson C; Giguère H; Alkayyal AA; Tai LH
Front Immunol; 2023; 14():1098344. PubMed ID: 36860852
[TBL] [Abstract][Full Text] [Related]
4. Peptides of tetraspanin oncoprotein CD151 trigger active immunity against primary tumour and experimental lung metastasis.
Lin W; Liu J; Chen J; Li J; Qiu S; Ma J; Lin X; Zhang L; Wu J
EBioMedicine; 2019 Nov; 49():133-144. PubMed ID: 31668880
[TBL] [Abstract][Full Text] [Related]
5. Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.
Salmaninejad A; Zamani MR; Pourvahedi M; Golchehre Z; Hosseini Bereshneh A; Rezaei N
Immunol Invest; 2016 Oct; 45(7):619-40. PubMed ID: 27603913
[TBL] [Abstract][Full Text] [Related]
6. Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.
Brito Baleeiro R; Liu P; Chard Dunmall LS; Di Gioia C; Nagano A; Cutmore L; Wang J; Chelala C; Nyambura LW; Walden P; Lemoine N; Wang Y
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586771
[TBL] [Abstract][Full Text] [Related]
7. Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer.
Aparicio B; Repáraz D; Ruiz M; Llopiz D; Silva L; Vercher E; Theunissen P; Tamayo I; Smerdou C; Igea A; Santisteban M; Gónzalez-Deza C; Lasarte JJ; Hervás-Stubbs S; Sarobe P
Front Immunol; 2022; 13():985886. PubMed ID: 36405725
[TBL] [Abstract][Full Text] [Related]
8. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
[TBL] [Abstract][Full Text] [Related]
9. A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines.
Feola S; Chiaro J; Martins B; Russo S; Fusciello M; Ylösmäki E; Bonini C; Ruggiero E; Hamdan F; Feodoroff M; Antignani G; Viitala T; Pesonen S; Grönholm M; Branca RMM; Lehtiö J; Cerullo V
Elife; 2022 Mar; 11():. PubMed ID: 35314027
[TBL] [Abstract][Full Text] [Related]
10. B19-VLPs as an effective delivery system for tumour antigens to induce humoral and cellular immune responses against triple negative breast cancer.
Jiménez-Chávez ÁJ; Nava-García BK; Bustos-Jaimes I; Moreno-Fierros L
Immunol Lett; 2021 Nov; 239():77-87. PubMed ID: 34508790
[TBL] [Abstract][Full Text] [Related]
11. Immunization using male germ cells and gametes as rich sources of cancer/testis antigens for inhibition of 4T1 breast tumors' growth and metastasis in BALB/c mice.
Safavi A; Kefayat A; Ghahremani F; Mahdevar E; Moshtaghian J
Int Immunopharmacol; 2019 Sep; 74():105719. PubMed ID: 31272065
[TBL] [Abstract][Full Text] [Related]
12. CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer.
Paret C; Simon P; Vormbrock K; Bender C; Kölsch A; Breitkreuz A; Yildiz Ö; Omokoko T; Hubich-Rau S; Hartmann C; Häcker S; Wagner M; Roldan DB; Selmi A; Türeci Ö; Sahin U
Oncotarget; 2015 Sep; 6(28):25356-67. PubMed ID: 26327325
[TBL] [Abstract][Full Text] [Related]
13. Novel peptide-based vaccine targeting heat shock protein 90 induces effective antitumor immunity in a HER2+ breast cancer murine model.
Kang J; Lee HJ; Lee J; Hong J; Hong Kim Y; Disis ML; Gim JA; Park KH
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36109084
[TBL] [Abstract][Full Text] [Related]
14. Cancer-testis antigens: promising targets for antigen directed antineoplastic immunotherapy.
Bodey B
Expert Opin Biol Ther; 2002 Aug; 2(6):577-84. PubMed ID: 12171503
[TBL] [Abstract][Full Text] [Related]
15. Tumor antigens and markers for breast and ovarian cancers.
Ghadersohi A; Chitta K; Greco WR; Harvey S; Winston J; Slocum H; Odunsi K; Sood AK
Front Biosci; 2002 Feb; 7():e48-57. PubMed ID: 11815284
[TBL] [Abstract][Full Text] [Related]
16. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
17. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
18. Neoantigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens.
Bekri S; Rodney-Sandy R; Gruenstein D; Mei A; Bogen B; Castle J; Levey D; Cho HJ
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190376
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic cancer/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy.
Yang P; Meng M; Zhou Q
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188558. PubMed ID: 33933558
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with post-translational modified, homocitrullinated peptides induces CD8 T-cell responses that mediate antitumor immunity.
Shah S; Cook KW; Symonds P; Weißer J; Skinner A; Al Omari A; Paston SJ; Pike I; Durrant LG; Brentville VA
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
